Argen-X
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more
Market Cap & Net Worth: Argen-X (ARGX)
Argen-X (BR:ARGX) has a market capitalization of $38.58 Billion (€37.59 Billion) as of March 30, 2026. Listed on the BR stock exchange, this Belgium-based company holds position #540 globally and #1 in its home market, demonstrating a 2.39% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Argen-X's stock price €607.40 by its total outstanding shares 61883406 (61.88 Million).
Argen-X Market Cap History: 2015 to 2026
Argen-X's market capitalization history from 2015 to 2026. Data shows growth from $708.27 Million to $38.58 Billion (49.50% CAGR).
Index Memberships
Argen-X is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BEL-20 INDEX
BEL20
|
$67.85 Billion | 56.13% | #1 of 20 |
|
BEL-20 INDEX
BFX
|
$67.85 Billion | 56.13% | #1 of 20 |
|
BEL All Share
BSPT
|
$140.83 Billion | 27.04% | #2 of 108 |
|
EuroNext 100
N100
|
$398.45 Billion | 9.56% | #5 of 97 |
Weight: Argen-X's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Argen-X Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Argen-X's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
17.53x
Argen-X's market cap is 17.53 times its annual revenue
1758.53x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
47.40x
Argen-X's market cap is 47.40 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $708.27 Million | $7.49 Million | -$16.74 Million | 94.52x | N/A |
| 2016 | $1.01 Billion | $15.47 Million | -$22.48 Million | 65.44x | N/A |
| 2017 | $3.34 Billion | $43.69 Million | -$33.68 Million | 76.36x | N/A |
| 2018 | $5.41 Billion | $24.57 Million | -$76.23 Million | 220.24x | N/A |
| 2019 | $9.12 Billion | $78.46 Million | -$181.21 Million | 116.26x | N/A |
| 2020 | $15.37 Billion | $41.24 Million | -$608.46 Million | 372.72x | N/A |
| 2021 | $20.03 Billion | $497.28 Million | -$408.26 Million | 40.28x | N/A |
| 2022 | $22.12 Billion | $410.75 Million | -$709.59 Million | 53.86x | N/A |
| 2023 | $21.82 Billion | $1.23 Billion | -$295.05 Million | 17.79x | N/A |
| 2024 | $38.11 Billion | $2.17 Billion | $804.13 Million | 17.53x | 47.40x |
Competitor Companies of ARGX by Market Capitalization
Companies near Argen-X in the global market cap rankings as of March 30, 2026.
Key companies related to Argen-X by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #170 globally with a market cap of $109.64 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #280 globally with a market cap of $72.69 Billion USD.
- CSL Ltd (PINK:CSLLY): Ranked #575 globally with a market cap of $35.87 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #336 globally with a market cap of $63.46 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #170 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.64 Billion | $433.07 |
| #280 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.69 Billion | $737.71 |
| #575 | CSL Ltd | PINK:CSLLY | $35.87 Billion | $74.44 |
| #336 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
Argen-X Historical Marketcap From 2015 to 2026
Between 2015 and today, Argen-X's market cap moved from $708.27 Million to $ 38.58 Billion, with a yearly change of 49.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €38.58 Billion | -15.26% |
| 2025 | €45.53 Billion | +19.47% |
| 2024 | €38.11 Billion | +74.67% |
| 2023 | €21.82 Billion | -1.38% |
| 2022 | €22.12 Billion | +10.47% |
| 2021 | €20.03 Billion | +30.29% |
| 2020 | €15.37 Billion | +68.52% |
| 2019 | €9.12 Billion | +68.54% |
| 2018 | €5.41 Billion | +62.22% |
| 2017 | €3.34 Billion | +229.49% |
| 2016 | €1.01 Billion | +42.96% |
| 2015 | €708.27 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 30th, 2026 the market cap of Argen-X was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.58 Billion USD |
| MoneyControl | $38.58 Billion USD |
| MarketWatch | $38.58 Billion USD |
| marketcap.company | $38.58 Billion USD |
| Reuters | $38.58 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.